Key Points
- Director Richard Gaynor purchased 1,731 shares at an average price of $18.91 for a total of $32,733.21, raising his stake to 56,630 shares (a 3.15% increase), as disclosed in an SEC Form 4 filing.
- Zai Lab shares traded around $18.47 (50-day MA $18.69, 200-day MA $22.81) and the company reported Q4 EPS of ($0.46), missing consensus by $0.02 while posting $127.6M in revenue; the firm has negative ROE and net margin and a market cap near $2.08B.
- Analyst views are mixed—recent price-target cuts from Cantor Fitzgerald and JPMorgan but coverage and buy ratings from others leave a MarketBeat average rating of "Moderate Buy" (average target $50)—while Royal Bank of Canada materially increased its stake and institutions own about 41.65% of the stock.
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) Director Richard Gaynor bought 1,731 shares of the firm's stock in a transaction that occurred on Tuesday, March 17th. The shares were acquired at an average price of $18.91 per share, with a total value of $32,733.21. Following the acquisition, the director owned 56,630 shares of the company's stock, valued at $1,070,873.30. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Zai Lab Price Performance
Zai Lab stock traded down $0.14 during mid-day trading on Friday, reaching $18.47. 85,012 shares of the company traded hands, compared to its average volume of 707,976. Zai Lab Limited Unsponsored ADR has a 52-week low of $15.96 and a 52-week high of $44.34. The firm's 50 day moving average price is $18.69 and its 200 day moving average price is $22.81. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -11.49 and a beta of 0.85.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.02). The firm had revenue of $127.60 million during the quarter, compared to the consensus estimate of $122.67 million. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, sell-side analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.
Wall Street Analysts Forecast Growth
ZLAB has been the topic of several recent analyst reports. Cantor Fitzgerald dropped their price objective on Zai Lab from $55.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, February 27th. JPMorgan Chase & Co. dropped their price target on shares of Zai Lab from $39.00 to $32.00 and set an "overweight" rating for the company in a research report on Wednesday. UBS Group began coverage on shares of Zai Lab in a research note on Wednesday, January 7th. They issued a "buy" rating and a $35.00 price objective for the company. Zacks Research downgraded Zai Lab from a "hold" rating to a "strong sell" rating in a research note on Friday, January 23rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Zai Lab in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $50.00.
View Our Latest Stock Report on ZLAB
Hedge Funds Weigh In On Zai Lab
An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada boosted its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 214.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,771 shares of the company's stock after buying an additional 9,390 shares during the quarter. Royal Bank of Canada's holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
